But Imfinzi's precise setting is uncertain, and big problems loom for companies pursuing similar trials.
ApexOnco Front Page
Recent articles
25 July 2024
Roche curbs its TIGIT push, while a co-stimulation crunch could be bad news for Regeneron.
24 July 2024
Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.
24 July 2024
An adcom on Imfinzi’s Aegean trial will show whether neoadjuvant and adjuvant benefits must be split out.
23 July 2024
ASP3082 grabs some early attention among degraders set to feature at ESMO.
22 July 2024
Early attention falls on ADCs originated by ProfoundBio, SystImmune, MediLink and Seagen.
22 July 2024
The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.
18 July 2024
The FDA throws out the company’s second attempt at an accelerated approval.